Hexima is pleased to announce positive results from Part 1 of its ongoing phase 1/2a clinical trial for HXP124 as a novel topical treatment for fungal nail infections (onychomycosis).

“HXP124 substantially reduced the area of infection in patients with a much shorter treatment period than current best‐in‐class therapies,” said Dr Nicole van der Weerden, Hexima’s CEO. “Because this is the first time this drug has been tested in humans, the data are necessarily from a relatively small number of patients. However, the results are still very encouraging and demonstrate the potential of HXP124 to be a best‐in‐class topical therapy.”

Click here to see the full announcement.